Return to homepagePandemic Pact

Tocilizumab for tReatment Of COVID-19 in intensive cARe patients ("TROCAR")

  • Funded by National Health and Medical Research Council (NHMRC)
  • Total publications:0 publications

Grant number: GA85494

Grant search

Key facts

  • Disease

    COVID-19

  • Start & end year

    2020
    2021

  • Known Financial Commitments (USD)

    $192,583.83

  • Funder

    National Health and Medical Research Council (NHMRC)

  • Principal Investigator

    N/A

  • Research Location

    Australia

  • Lead Research Institution

    QIMR Berghofer Medical Research Institute

  • Research Priority Alignment

    N/A

  • Research Category

    Therapeutics research, development and implementation

  • Research Subcategory

    Prophylactic use of treatments

  • Special Interest Tags

    N/A

  • Study Type

    Clinical

  • Clinical Trial Details

    Unspecified

  • Broad Policy Alignment

    Pending

  • Age Group

    Unspecified

  • Vulnerable Population

    Unspecified

  • Occupations of Interest

    Unspecified

Abstract

Severe illness from COVID-19 is associated with a high risk of death. Currently, no proven treatment exists. We will conduct a clinical trial to determine if tocilizumab, a drug used to reduce the adverse effects of inflammation, will improve clinical outcomes in critically ill patients with COVID-19. We will enrol 194 patients from intensive care units in Brisbane, and will determine if a single dose of tocilizumab reduces the duration of ventilatory support, and reduces the risk of death.